Vernalis &r&d) Ltd.

Les Laboratoires Servier

Les Laboratories Servier

Vernalis Limited

Christopher John Graham

Guillaume De Nanteuil

Arnaud Le Tiran

Olivier Geneste

James Brooke Murray

I-Jen Chen

James Edward Paul Davidson

Patrick Casara

Thierry Le Diguarher

Jean-Michel Henlin

Paul Brough

Alba Macias

Stephen Roughley

Steven Walls

Terance Hart

Rachel Parsons

Jérôme-Benoît Starck

Stuart Christopher Ray

John Hickman

Miklós Nyerges

Stéphane Depil

Simon Bedford

Claire Walmsley

Stephen Stokes

Daniel Maddox

Emma Jayne Stefaniak

Jéröme-Benoit Starck

Jerome-Benoit Starck

James Edward Davidson

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Azetidine derivatives

The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and Rare as defined in the claims. 

1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors

Compounds of formula (I): wherein R, R, R, R, R, R, R, A, A, T and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I): wherein R, R, R, R, R, R, R, R, R, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them

1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors

Compounds of formula (I): wherein R, R, R, R, R, R, R, A, A, T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Formula (I) Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms. 

Azetidine derivatives as FAAH inhibitors

Growing community of inventors

Newmarket, United Kingdom

Christopher John Graham